Fundraising Fox

IpiNovyx Bio

West Nyack, US · Founded 2021 · Delaware corporation · 1 known investors

ipinovyx.com

IpiNovyx Bio is a biotech company developing potent and selective immunoproteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases. Its technology originated from research at Weill Cornell Medicine and the Hospital for Special Surgery, and it is advancing these preclinical programs toward clinical applications.

BiotechHealthtechMedical Devices

Founders & leadership

MA
Marc AppelNamed on SEC filing
LG
Lutz GiebelNamed on SEC filing
JG
James GrahamNamed on SEC filing
GL
Gang LinScientific Founder
CN
Carl NathanScientific Founder
FB
Franck BarratScientific Founder

Investors · 1

Reported raises · per SEC filings

Form D private placements

$7M disclosed across 1 round · 2021

$7MraisedOct 2021 · 12 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Marc AppelExecutive Officer, Director
  • Lutz GiebelDirector
  • James GrahamDirector
Offering amount
$10M
Amount sold
$7M
First sale
Sep 2021
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does IpiNovyx Bio do?
IpiNovyx Bio is a biotech company developing potent and selective immunoproteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases. Its technology originated from research at Weill Cornell Medicine and the Hospital for Special Surgery, and it is advancing these preclinical programs toward clinical applications.
Who are IpiNovyx Bio's investors?
IpiNovyx Bio's investors include Pathway Bioventures.
How much funding has IpiNovyx Bio raised?
IpiNovyx Bio has disclosed $7M raised across 1 round.
Where is IpiNovyx Bio headquartered?
IpiNovyx Bio is headquartered in West Nyack, US.